On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy. For more information, read the FDA announcement and the Partner Therapeutics press release.
On May 8, the FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring a neuregulin 1 gene fusion with disease progression on or after prior systemic therapy.
For more information, read the FDA announcement and the Partner Therapeutics press release.
The 2026 NCCN Fall Policy Summit explored the current state of cancer screening and prevention services in the US, barriers that still drive disparities in screening uptake, and strategies to shift the paradigm of preventive cancer care.
